曲美他嗪治疗慢性充血性心力衰竭临床疗效及安全性分析.docVIP

曲美他嗪治疗慢性充血性心力衰竭临床疗效及安全性分析 　　DOI：10.16662/j.cnki.1674-0742.2017.11.150 [摘要] 目的 探?曲美他嗪治疗慢性充血性心力衰竭临床疗效，同时分析其安全性。 方法 方便选取2015年6月―2016年12月于该院就诊并选择曲美他嗪进行治疗的慢性充血性心力衰竭患者86例作为观察组，同时选取同期于该院进行常规药物治疗的慢性充血性心力衰竭患者86例作为对照组。将两组患者的临床疗效、左心室收缩、舒张末期内径及射血分数和不良反应发生情况进行对比。 结果 观察组（94.2%）患者治疗效果显著优于对照组（79.1%）（P0.05），治疗后观察组的左心室收缩、舒张末期内径分别为（41.3±3.3）、（57.6±5.8） mm，均显著小于对照组的（52.5±4.2）、（65.0±6.2）mm，差异有统计学意义（P0.05）；治疗前后肝肾功能、血常规情况均无显著变化（P0.05）。 结论 曲美他嗪治疗慢性充血性心力衰竭临床疗效显著，可改善患者心肌功能，同时安全性较高 [关键词] 曲美他嗪；慢性充血性心力衰竭；临床疗效；安全性 [中图分类号] R541.6 [文献标识码] A [文章编号] 1674-0742（2017）04（b）-0150-03 Analysis of Clinical Curative Effect and Safety of Trimetazidine in Treatment of Chronic congestive Heart Failure ZHANG Xuan1， LIU Xin-qiong2 1.Department of Cardiovascular Medicine， Yili Xinjiang Xinhua Hospital， Yili， Xinjiang， 835000 China；2.Department of Endocrinology， Yili Xinjiang Xinhua Hospital， Yili， Xinjiang， 835000 China [Abstract] Objective To discuss the clinical curative effect and safety of trimetazidine in treatment of chronic congestive heart failure. Methods 86 cases of patients with chronic congestive heart failure treated with trimetazidine diagnosed in our hospital from June 2015 to December 2016 were convenient selected as the observation group， while 86 cases of patients with chronic congestive heart failure treated with routine drugs in our hospital were selected as the control group， and the clinical curative effect， left ventricular systolic index， end-diastolic diameter， ejection fraction and occurrence of adverse reactions were compared between the two groups. Results The treatment effect in the observation group was obviously better than that in the control group（94.2% vs 79.1%）（P0.05）， after treatment， the left ventricular systolic index and end-diastolic diameter in the observation group were obviously fewer than those in the control group[（41.3±3.3）、（57.6±5.8）mm vs（52.5±4.2）、（65.0±6.2）mm]，the difference was statistically signifieant （P0.05）；the liver function renal function